DOUG DANISON

Head of Europe, Bluebird Bio

Doug Danison has served as our head of Europe since January 2021. He joined bluebird bio in July 2015 to establish the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES).

Doug has more than 20 years of Pricing & Market Access experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology and now bluebird bio. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management. While addressing market access challenges from a variety of vantage points including Global, European Regional, and U.S. roles he’s built teams, processes, and a knowledgebase that enables the execution of market access strategies which anticipate and meet the needs of access decision makers in an increasing challenging market access environment.

 LIVE ONLINE

20 May 2021

BOOK YOUR PLACE NOW